<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-163568" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Char Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bongurala</surname>
            <given-names>Archana Reddy</given-names>
          </name>
          <aff>Omni Family Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Romero-Lopez</surname>
            <given-names>Mar</given-names>
          </name>
          <aff>UT Health - McGovern Medical School</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Archana Reddy Bongurala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mar Romero-Lopez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-163568.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Char syndrome is a rare autosomal dominant disorder characterized by the triad of atypical facial features, patent ductus arteriosus (PDA), and aplasia or hypoplasia of the middle phalanges of the fifth fingers.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref>&#x000a0;Florence Char, who described a child in whom PDA was associated with low-set ears, ptosis, short philtrum, and "duck-bill" lips, first reported the syndrome in 1978.<xref ref-type="bibr" rid="article-163568.r2">[2]</xref>&#x000a0;</p>
        <p>Typical facial features include a depressed nasal bridge and broad flat nasal tip, widely spaced eyes, down-slanted palpebral fissures, mild ptosis, a short philtrum with prominent philtrum ridges with an upward pointing vermilion border resulting in a triangular mouth and thickened (patulous) everted lips.<xref ref-type="bibr" rid="article-163568.r3">[3]</xref>&#x000a0;The most commonly identified cardiac anomaly is PDA.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref>&#x000a0;Less common findings include other types of congenital heart defects, other hand and foot anomalies, hypodontia, hearing loss, myopia and/or strabismus, polythelia, parasomnia, craniosynostosis (involving either the metopic or sagittal suture), and short stature.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref><xref ref-type="bibr" rid="article-163568.r3">[3]</xref><xref ref-type="bibr" rid="article-163568.r4">[4]</xref></p>
      </sec>
      <sec id="article-163568.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact etiology of Char syndrome is&#x000a0;still unknown. Recent research suggests that Char syndrome may be caused by mutations in the transcription factor AP-2 Beta (<italic toggle="yes">TFAP2B</italic>) gene.<xref ref-type="bibr" rid="article-163568.r5">[5]</xref>&#x000a0;The disorder is inherited in an autosomal dominant manner, meaning that a single copy of the mutated gene is sufficient to cause the condition.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref>&#x000a0;The condition shows complete penetrance but variable expressivity, meaning the mutated gene will always cause the disorder, but the severity of symptoms may vary.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref>&#x000a0;Frequently noted pathogenic variants in the&#x000a0;<italic toggle="yes">TFAP2B</italic>&#x000a0;gene are missense mutations in the coding region, which is critical for DNA binding.<xref ref-type="bibr" rid="article-163568.r6">[6]</xref><xref ref-type="bibr" rid="article-163568.r7">[7]</xref> Other reported mutations include intronic point mutations and frameshift deletions.<xref ref-type="bibr" rid="article-163568.r5">[5]</xref><xref ref-type="bibr" rid="article-163568.r8">[8]</xref></p>
      </sec>
      <sec id="article-163568.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Char syndrome is an extremely rare disorder, with only a few dozen cases reported worldwide.<xref ref-type="bibr" rid="article-163568.r2">[2]</xref>&#x000a0;The prevalence of Char syndrome is difficult to determine due to its rarity and the possibility of under-diagnosis. However, based on the limited available data, it is believed to occur in approximately&#x000a0;1 in every 100,000 to 200,000 births.<xref ref-type="bibr" rid="article-163568.r9">[9]</xref>&#x000a0;Char syndrome affects both males and females equally and has been reported in various ethnic groups.<xref ref-type="bibr" rid="article-163568.r9">[9]</xref></p>
      </sec>
      <sec id="article-163568.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Char syndrome arises from a mutation in the <italic toggle="yes">TFAP2B</italic> gene<bold>.</bold><xref ref-type="bibr" rid="article-163568.r10">[10]</xref> This gene acts as a molecular switch controlling other genes during embryonic development. It plays a critical role in embryonic development and acts as a transcription factor that regulates the expression of genes involved in the development of the neural crest, a transient embryonic structure that gives rise to&#x000a0;various tissues and organs, including the facial structures, the heart, and the limbs.<xref ref-type="bibr" rid="article-163568.r10">[10]</xref>&#x000a0;Mutations in the <italic toggle="yes">TFAP2B</italic> gene disrupt the normal function of the transcription factor, leading to the characteristic features observed in individuals with Char syndrome, with abnormal development of the eyes, nasal passages, heart, and other affected structures.<xref ref-type="bibr" rid="article-163568.r6">[6]</xref><xref ref-type="bibr" rid="article-163568.r3">[3]</xref><xref ref-type="bibr" rid="article-163568.r11">[11]</xref></p>
      </sec>
      <sec id="article-163568.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The clinical presentation of Char syndrome exhibits a spectrum of severity. This variability necessitates a tailored approach to diagnosis and management for each patient.</p>
        <p>Facial dysmorphism is a prominent feature present in &#x0003e;80% of the patients,&#x000a0;often characterized by flattened cheekbones, a depressed nasal bridge, a broad and prominent nose with a short philtrum and prominent philtral ridges, mild ptosis, downward-slanted palpebral fissures with widely spaced eyes, a prominent vermilion border with upward slant forming a triangular-shaped mouth with thick and everted lips.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref><xref ref-type="bibr" rid="article-163568.r12">[12]</xref></p>
        <p>Cardiac malformations are another hallmark, with PDA being the most common defect in 68% of the patients.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref>&#x000a0;PDA is a fetal vascular connection between the main pulmonary artery and the systemic aorta that typically closes shortly after birth.<xref ref-type="bibr" rid="article-163568.r12">[12]</xref>&#x000a0;In individuals with Char syndrome, it can remain open, leading to left to right shunting (from systemic to pulmonary circulation), disrupting the normal blood flow, leading to increased pulmonary blood flow and pulmonary hypertension if not corrected.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref>&#x000a0;Affected infants can present with symptoms like tachypnea, difficulty feeding, and failure to thrive. Untreated PDA, in severe cases, can contribute to cardiac failure.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref>&#x000a0;Other potential cardiac anomalies associated with Char syndrome include septal defects and valve malformations in 6% of patients.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref><xref ref-type="bibr" rid="article-163568.r2">[2]</xref></p>
        <p>Hand abnormalities are a variable feature of Char syndrome, present in 57% of the cases.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref>&#x000a0;These can range from clinodactyly (the pinky finger may bend inwards towards the ring finger), hypoplasia or aplasia of middle phalanges of the fifth finger (under-development or complete absence of middle bone segments), syndactyly (fused fingers), or brachydactyly.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref></p>
        <p>Less common findings include myopia, strabismus, hearing abnormality (including profound bilateral hearing loss), skeletal anomalies, craniosynostosis (including metopic or sagittal sutures), hypodontia (lack of second or third molars), short stature and intellectual disability.<xref ref-type="bibr" rid="article-163568.r13">[13]</xref></p>
      </sec>
      <sec id="article-163568.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The evaluation of individuals with suspected Char syndrome typically involves a combination of clinical assessment, imaging studies, and genetic testing. Clinical assessment includes a detailed medical history and thorough physical examination focusing on any congenital anomalies affecting the eyes, ears, heart, and teeth.<xref ref-type="bibr" rid="article-163568.r14">[14]</xref></p>
        <p>Imaging studies, such as computed tomography (CT) or magnetic resonance imaging (MRI), are used to further evaluate the structural abnormalities in the eyes, ears, and other affected organs. Echocardiography is used to diagnose PDA and other associated cardiac anomalies.<xref ref-type="bibr" rid="article-163568.r15">[15]</xref>&#x000a0;&#x000a0;</p>
        <p>Genetic testing plays an important role in confirming the diagnosis of Char syndrome, identifying causative mutations, and for genetic counseling. Genetic testing can identify mutations in the gene (heterogenic pathogenic variant).<xref ref-type="bibr" rid="article-163568.r16">[16]</xref><xref ref-type="bibr" rid="article-163568.r17">[17]</xref>&#x000a0;Different modalities of molecular genetic testing can include gene-targeted sequencing and whole-exome sequencing. In&#x000a0;individuals presenting with symptoms suggestive of Char syndrome, gene-targeted sequencing such as single gene testing and multi-gene panels are used, while in&#x000a0;individuals where Char syndrome is not considered, whole-exome sequencing or gene panel testing is utilized.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref><xref ref-type="bibr" rid="article-163568.r16">[16]</xref> Selecting the most suitable testing requires careful analysis of clinical features, differential diagnosis, and available resources.</p>
      </sec>
      <sec id="article-163568.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management of Char syndrome requires a comprehensive, multidisciplinary approach, addressing the specific symptoms and complications associated with the disorder.<xref ref-type="bibr" rid="article-163568.r4">[4]</xref>&#x000a0;Understanding its etiology and pathophysiology is important in providing proper care and support. Depending on the manifestations of a particular patient, multidisciplinary teams involving various specialties, such as pediatricians, geneticists, craniofacial surgeons, cardiologists, ophthalmologists, otolaryngologists, and orthopedic surgeons, may be involved.&#x000a0;</p>
        <p>Treatment may include surgical correction of congenital cardiac defects, repair of choanal atresia, and management of eye and ear anomalies.<xref ref-type="bibr" rid="article-163568.r12">[12]</xref>&#x000a0;Therapeutic efforts prioritize the correction of hemodynamic abnormalities. Post-neonatal PDA management is guided by the degree of shunting between the aorta and the pulmonary artery.<xref ref-type="bibr" rid="article-163568.r2">[2]</xref><xref ref-type="bibr" rid="article-163568.r18">[18]</xref>&#x000a0;Surgical ligation and catheter-based ductal occlusion are the definitive therapeutic options for the management of PDA.<xref ref-type="bibr" rid="article-163568.r8">[8]</xref><xref ref-type="bibr" rid="article-163568.r19">[19]</xref>&#x000a0;Craniofacial surgery&#x000a0;can address some aspects of facial dysmorphism, aiming to improve aesthetics and potentially alleviate functional difficulties. However, these procedures are complex and require careful consideration of risks and benefits. In addition, patients with Char syndrome require annual surveillance for vision and hearing, dental checkups every 6 months, assessment of signs and symptoms of sleep disorder every 6 months, and monitoring of head shape and size at every visit in infancy.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref><xref ref-type="bibr" rid="article-163568.r20">[20]</xref>&#x000a0;Early diagnosis and intervention are crucial to optimize developmental outcomes and quality of life.<xref ref-type="bibr" rid="article-163568.r4">[4]</xref></p>
        <p>Genetic counseling plays a significant role in the management of Char syndrome, providing families with information about the inheritance pattern of the condition and the potential risk of having affected offspring in future pregnancies.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref>&#x000a0;Char syndrome follows an autosomal dominant inheritance pattern.<xref ref-type="bibr" rid="article-163568.r21">[21]</xref>&#x000a0;In&#x000a0;individuals with Char syndrome who have an affected parent, there is a 50% chance of passing the mutated gene on to their children. However, Char syndrome can also occur in&#x000a0;those with no family history of the condition due to a new mutation in the <italic toggle="yes">TFAP2B</italic> gene. These are known as de novo mutations, and the risk to the siblings of a proband appears to be low. Prenatal diagnosis can be performed through chorionic villus sampling (CVS) or amniocentesis to identify the presence of the mutation in the developing fetus.<xref ref-type="bibr" rid="article-163568.r5">[5]</xref></p>
      </sec>
      <sec id="article-163568.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>When evaluating a patient for Char syndrome, it is crucial to consider a range of differential diagnoses due to the overlap of clinical features with other genetic disorders. These conditions may share similarities in facial anomalies, congenital heart defects, and limb abnormalities, necessitating thorough genetic and clinical assessments to accurately distinguish Char syndrome from other potential diagnoses. Differential diagnoses for Char syndrome include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>22q11.2 deletion syndrome (Di George syndrome)&#x000a0;<xref ref-type="bibr" rid="article-163568.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Holt-Oram syndrome</p>
          </list-item>
          <list-item>
            <p>Treacher Collins syndrome&#x000a0;<xref ref-type="bibr" rid="article-163568.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Cri-du-chat syndrome</p>
          </list-item>
          <list-item>
            <p>Rubinstein-Taybi syndrome&#x000a0;<xref ref-type="bibr" rid="article-163568.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Ellis-van Creveld syndrome&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-163568.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for individuals with Char syndrome can vary depending on the severity of cardiac defects and associated comorbidities.&#x000a0;Early intervention and management of cardiac abnormalities can significantly improve outcomes and quality of life for affected individuals.<xref ref-type="bibr" rid="article-163568.r1">[1]</xref>&#x000a0;However, some individuals may experience long-term complications, such as intellectual disability, visual impairment, and heart failure.<xref ref-type="bibr" rid="article-163568.r4">[4]</xref></p>
      </sec>
      <sec id="article-163568.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Char syndrome can lead to complications that significantly impact the quality of life and overall health of affected individuals. They may be at risk of various complications, including respiratory distress due to choanal atresia, feeding difficulties, hearing loss, developmental disabilities, and skeletal abnormalities.<xref ref-type="bibr" rid="article-163568.r25">[25]</xref>&#x000a0;</p>
        <p>Cardiac anomalies, particularly PDA, can result in heart failure and other cardiovascular issues if not properly managed. Facial and limb abnormalities may cause functional impairments and require surgical interventions. Additionally, the psychosocial effects of visible physical anomalies can affect self-esteem and social interactions.&#x000a0;</p>
      </sec>
      <sec id="article-163568.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Due to its rarity, preventive measures for Char syndrome are limited. However, genetic counseling and prenatal testing become crucial for families with a history of the condition. Carrier screening and prenatal diagnosis options like CVS or amniocentesis can identify potential carriers and diagnose affected fetuses.</p>
        <p>Education empowers patients and families by providing comprehensive knowledge about Char syndrome's genetics, clinical variability, and prognosis. It outlines current treatment options and future advancements and emphasizes the importance of multidisciplinary care, including medication management, complication prevention, and regular follow-up. Additionally, connecting&#x000a0;patients and families with support resources fosters active participation in care, ultimately improving their quality of life.</p>
      </sec>
      <sec id="article-163568.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Char syndrome is a rare condition, and research efforts are ongoing to gain a deeper understanding of the genetic and developmental processes involved. With a limited number of reported cases, further research is needed to define the full spectrum of clinical features associated with Char syndrome. This&#x000a0;may involve collaborative efforts at various institutions to create a large patient registry.</p>
        <p>Advanced genetic and neuroimaging techniques can help understand the pathophysiology and identify potential genotype-phenotype correlation. This knowledge is essential for exploring potential therapeutic options, including gene therapy approaches that could offer a more definitive future solution.</p>
        <p>Additionally, it is crucial to establish dedicated support networks for individuals and families affected by Char syndrome. These networks can provide much-needed resources, foster a sense of community, and empower individuals to navigate the challenges associated with the condition.</p>
        <p>The complex nature of Char syndrome necessitates a comprehensive and interdisciplinary approach to care and management. Advancements in understanding its genetic basis and the development of targeted interventions will continue to improve the quality of life for individuals living with Char syndrome.</p>
      </sec>
      <sec id="article-163568.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Char syndrome's complex presentation necessitates a collaborative approach from a well-coordinated interprofessional healthcare team.&#x000a0;Physicians, advanced care practitioners, and nurses need strong communication skills to share observations, interpret diagnostic tests, and develop a comprehensive care plan. Pharmacists play a vital role in ensuring safe and effective medication management, while therapists can address developmental delays and improve quality of life.</p>
        <p>Effective care coordination, facilitated by nurses and care coordinators, ensures seamless transitions between specialists and avoids treatment gaps. By working together, the team can prioritize patient-centered care, ensuring treatment decisions reflect individual and family needs and goals. This collaborative approach optimizes patient safety, improves outcomes, and ultimately enhances team performance in delivering exceptional care for individuals with Char syndrome.</p>
      </sec>
      <sec id="article-163568.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=163568&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=163568">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/char-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=163568">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/163568/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=163568">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-163568.s15">
        <title>References</title>
        <ref id="article-163568.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gelb</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <chapter-title>Char Syndrome</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2003</year>
            <month>8</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">20301285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Slavotinek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clayton-Smith</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Super</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Familial patent ductus arteriosus: a further case of CHAR syndrome.</article-title>
            <source>Am J Med Genet</source>
            <year>1997</year>
            <month>Aug</month>
            <day>08</day>
            <volume>71</volume>
            <issue>2</issue>
            <fpage>229</fpage>
            <page-range>229-32</page-range>
            <pub-id pub-id-type="pmid">9217229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nyboe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kreiborg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Darvann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dun&#x000f8;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nissen</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Hove</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>A study of familial Char syndrome involving the TFAP2B gene with a focus on facial shape characteristics.</article-title>
            <source>Clin Dysmorphol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>71</fpage>
            <page-range>71-77</page-range>
            <pub-id pub-id-type="pmid">29683802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Massaad</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tfayli</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Awwad</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nabulsi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farra</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Char Syndrome a novel mutation and new insights: A clinical report.</article-title>
            <source>Eur J Med Genet</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>62</volume>
            <issue>12</issue>
            <fpage>103607</fpage>
            <pub-id pub-id-type="pmid">30579973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Satoda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Burn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goodship</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Pierpont</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Gelb</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus.</article-title>
            <source>Nat Genet</source>
            <year>2000</year>
            <month>May</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <page-range>42-6</page-range>
            <pub-id pub-id-type="pmid">10802654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raap</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gierendt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kreipe</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Christgen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Transcription factor AP-2beta in development, differentiation and tumorigenesis.</article-title>
            <source>Int J Cancer</source>
            <year>2021</year>
            <month>Sep</month>
            <day>15</day>
            <volume>149</volume>
            <issue>6</issue>
            <fpage>1221</fpage>
            <page-range>1221-1227</page-range>
            <pub-id pub-id-type="pmid">33720400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Tfap2b mutation in mice results in patent ductus arteriosus and renal malformation.</article-title>
            <source>J Surg Res</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>227</volume>
            <fpage>178</fpage>
            <page-range>178-185</page-range>
            <pub-id pub-id-type="pmid">29804851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Farhi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carew</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Warnes</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nelson-Williams</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Pober</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>State</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Lifton</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Syndromic patent ductus arteriosus: evidence for haploinsufficient TFAP2B mutations and identification of a linked sleep disorder.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2005</year>
            <month>Feb</month>
            <day>22</day>
            <volume>102</volume>
            <issue>8</issue>
            <fpage>2975</fpage>
            <page-range>2975-9</page-range>
            <pub-id pub-id-type="pmid">15684060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Weismann</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Satoda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pierpont</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Gelb</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Novel TFAP2B mutations that cause Char syndrome provide a genotype-phenotype correlation.</article-title>
            <source>Am J Hum Genet</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>695</fpage>
            <page-range>695-703</page-range>
            <pub-id pub-id-type="pmid">11505339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khetyar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Syrris</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tinworth</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abushaban</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Novel TFAP2B mutation in nonsyndromic patent ductus arteriosus.</article-title>
            <source>Genet Test</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>457</fpage>
            <page-range>457-9</page-range>
            <pub-id pub-id-type="pmid">18752453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanasubsinn</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sittiwangkul</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pongprot</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kawasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohazama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sastraruji</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaewgahya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kantaputra</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <article-title>TFAP2B mutation and dental anomalies.</article-title>
            <source>J Hum Genet</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>62</volume>
            <issue>8</issue>
            <fpage>769</fpage>
            <page-range>769-775</page-range>
            <pub-id pub-id-type="pmid">28381879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bertola</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Sugayama</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Utagawa</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Albano</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Further delineation of Char syndrome.</article-title>
            <source>Pediatr Int</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-8</page-range>
            <pub-id pub-id-type="pmid">10703243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Babao&#x0011f;lu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oru&#x000e7;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x000fc;nlemez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gelb</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Char syndrome, a familial form of patent ductus arteriosus, with a new finding: hypoplasia [corrected] of the 3rd finger.</article-title>
            <source>Anadolu Kardiyol Derg</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>523</fpage>
            <page-range>523-4</page-range>
            <pub-id pub-id-type="pmid">22728731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Satoda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pierpont</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Bornemeier</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gelb</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Char syndrome, an inherited disorder with patent ductus arteriosus, maps to chromosome 6p12-p21.</article-title>
            <source>Circulation</source>
            <year>1999</year>
            <month>Jun</month>
            <day>15</day>
            <volume>99</volume>
            <issue>23</issue>
            <fpage>3036</fpage>
            <page-range>3036-42</page-range>
            <pub-id pub-id-type="pmid">10368122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galzerano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pergola</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Eltayeb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ludovica</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Arbili</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tashkandi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Michele</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Barchitta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parato</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Salvo</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Echocardiography in Simple Congenital Heart Diseases: Guiding Adult Patient Management.</article-title>
            <source>J Cardiovasc Echogr</source>
            <year>2023</year>
            <season>Oct-Dec</season>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>171</fpage>
            <page-range>171-182</page-range>
            <pub-id pub-id-type="pmid">38486692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ji</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bhattacharya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Characterization of transcription factor AP-2 &#x003b2; mutations involved in familial isolated patent ductus arteriosus suggests haploinsufficiency.</article-title>
            <source>J Surg Res</source>
            <year>2014</year>
            <month>May</month>
            <day>15</day>
            <volume>188</volume>
            <issue>2</issue>
            <fpage>466</fpage>
            <page-range>466-472</page-range>
            <pub-id pub-id-type="pmid">24507797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kiel</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Kenny</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Cornell</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Nichols</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Van Otterloo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>TFAP2 paralogs regulate midfacial development in part through a conserved ALX genetic pathway.</article-title>
            <source>Development</source>
            <year>2024</year>
            <month>Jan</month>
            <day>01</day>
            <volume>151</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">38063857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lemmers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vijlbrief</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Benders</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alderliesten</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Veldhuis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baerts</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Koopman-Esseboom</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Groenendaal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van Bel</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Delayed Surgical Closure of the Patent Ductus Arteriosus: Does the Brain Pay the Price?</article-title>
            <source>J Pediatr</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>254</volume>
            <fpage>25</fpage>
            <page-range>25-32</page-range>
            <pub-id pub-id-type="pmid">36241053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahmoud</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Youssef</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cinteza</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Voicu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Balan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Margarint</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Filip</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nicolae</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Duica</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nicolescu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barascu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cirstoveanu</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Ductus Arteriosus Stenting in Newborns - Transcatheter Approach as a Bridge Therapy for Corrective Surgery.</article-title>
            <source>Maedica (Bucur)</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>205</fpage>
            <page-range>205-210</page-range>
            <pub-id pub-id-type="pmid">35733737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fujiyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nagata</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kashiwagi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ikkyu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takagi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tatsuzawa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kakizaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kanuka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sugiyama</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Funato</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sakurai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yanagisawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Sleep Architecture in Mice Is Shaped by the Transcription Factor AP-2&#x003b2;.</article-title>
            <source>Genetics</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>216</volume>
            <issue>3</issue>
            <fpage>753</fpage>
            <page-range>753-764</page-range>
            <pub-id pub-id-type="pmid">32878901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaughan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Basson</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Molecular determinants of atrial and ventricular septal defects and patent ductus arteriosus.</article-title>
            <source>Am J Med Genet</source>
            <year>2000</year>
            <season>Winter</season>
            <volume>97</volume>
            <issue>4</issue>
            <fpage>304</fpage>
            <page-range>304-9</page-range>
            <pub-id pub-id-type="pmid">11376442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cillo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Coppola</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Habetswallner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cecere</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pignata</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Toriello</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Rosa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grilli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ammendola</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salerno</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cirillo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Merla</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Riccio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pignata</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giardino</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Understanding the Variability of 22q11.2 Deletion Syndrome: The Role of Epigenetic Factors.</article-title>
            <source>Genes (Basel)</source>
            <year>2024</year>
            <month>Feb</month>
            <day>29</day>
            <volume>15</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">38540380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gil Rosas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Centola</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mouguelar</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Piga</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Calcaterra</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Armas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Coux</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The transcription of the main gene associated with Treacher-Collins syndrome (TCOF1) is regulated by G-quadruplexes and cellular nucleic acid binding protein (CNBP).</article-title>
            <source>Sci Rep</source>
            <year>2024</year>
            <month>Mar</month>
            <day>29</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>7472</fpage>
            <pub-id pub-id-type="pmid">38553547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacombe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bloch-Zupan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bredrup</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Houge</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Mi&#x000f1;a&#x000fa;r</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kayserili</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Larizza</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lopez Gonzalez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Menke</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Milani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saettini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Tooke</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Van der Zee</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Van Genderen</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Van-Gils</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Waite</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Adrien</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bartsch</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bitoun</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bouts</surname>
                <given-names>AHM</given-names>
              </name>
              <name>
                <surname>Cueto-Gonz&#x000e1;lez</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Dominguez-Garrido</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Duijkers</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Fergelot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Halstead</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Huisman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Meossi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mullins</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nikkel</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Oliver</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Prada</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Riddle</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rodriguez-Fonseca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez Pena</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Santos-Simarro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Szakszon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taupiac</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Totaro</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Valenzuena Palafoll</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Van Der Kaay</surname>
                <given-names>DCM</given-names>
              </name>
              <name>
                <surname>Van Wijk</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Vyshka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wiley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hennekam</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management in Rubinstein-Taybi syndrome: first international consensus statement.</article-title>
            <source>J Med Genet</source>
            <year>2024</year>
            <month>May</month>
            <day>21</day>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>503</fpage>
            <page-range>503-519</page-range>
            <pub-id pub-id-type="pmid">38471765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-163568.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edward</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>D'Gama</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wojcik</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Brownstein</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kenna</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Majzoub</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>A novel missense mutation in TFAP2B associated with Char syndrome and central diabetes insipidus.</article-title>
            <source>Am J Med Genet A</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>179</volume>
            <issue>7</issue>
            <fpage>1299</fpage>
            <page-range>1299-1303</page-range>
            <pub-id pub-id-type="pmid">31012281</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
